Home › Funds › Sofinnova Investments, Inc. › SUPN

Sofinnova Investments, Inc. position in SUPN

SUPERNUS PHARMACEUTICALS · Health Care

Sofinnova Investments, Inc. reported holding 1,036,328 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$48.2M, representing 2.57% of its reported portfolio and ranking #10 among its reported holdings. Sofinnova Investments, Inc. has disclosed SUPN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)1.04M sh
Reported value held$48.20M
Portfolio Weight2.57%
First reportedQ1 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sofinnova Investments, Inc.'s SUPN position evolved

Sofinnova Investments, Inc. first disclosed a stake in SUPN in Q1 2025 at 520,678 shares (US$17.1M). The position peaked in Q1 2026 at 954,309 shares, worth US$49.3M. Across 6 filings, Sofinnova Investments, Inc. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,036,328 shares valued at US$48.2M — an increase of 82,019 shares quarter over quarter.. Notable position changes include a 54% increase in Q2 2025 (shares rose 52% over the following quarter), a 53% trim in Q3 2025 (shares rose 4% over the following quarter), a 73% increase in Q1 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 520.68K $17.05M New
Q2 2025 799.25K $25.19M Add
Q3 2025 377.07K $18.02M Reduce
Q4 2025 553.10K $27.49M Add
Q1 2026 954.31K $49.33M Add
Q2 2026 1.04M $48.20M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SUPN and 13F data

SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 34 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$123.1M), ASHFORD CAPITAL MANAGEMENT INC (US$28.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SUPN

All SUPN fund holders →

FAQ

How long has Sofinnova Investments, Inc. held SUPN?

Sofinnova Investments, Inc. has disclosed SUPN holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Sofinnova Investments, Inc.'s current position in SUPN?

As of Q2 2026, Sofinnova Investments, Inc. holds 1.04M shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $48.20M, representing 2.57% of its reported portfolio and ranking #10.

Has Sofinnova Investments, Inc. been buying or selling SUPN?

In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in SUPN. The position peaked in Q1 2026 at 954.31K shares.

Which other funds hold SUPN?

Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, ASHFORD CAPITAL MANAGEMENT INC, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.